Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both upper and lower motor neurons. The oculomotor system—controlling eye movements—is relatively spared until late stages of disease, making it a window into disease progression and therapeutic targeting. The neurons controlling eye movements exhibit unique vulnerability patterns in ALS that distinguish them from spinal motor neurons.
| Property |
Value |
| Category |
Motor neurons (cranial) |
| Species |
Human |
| Brain Regions |
Oculomotor nucleus, trochlear nucleus, abducens nucleus, paramedian pontine reticular formation |
| Neurotransmitters |
Glutamate, acetylcholine |
| Function |
Eye movement control |
The oculomotor nucleus controls most extraocular muscles:
Motor neurons
- Superior rectus ( contralateral)
- Inferior rectus
- Medial rectus
- Inferior oblique
- Levator palpebrae superioris (bilateral)
Parasympathetic output
- Edinger-Westphal nucleus
- Preganglionic parasympathetic neurons
- Postganglionic: ciliary ganglion → sphincter pupillae, ciliary muscle
- Superior oblique muscle (contralateral)
- Smallest cranial nerve nucleus
- Unique decussation
- Lateral rectus muscle (ipsilateral)
- Internuclear neurons (MLF)
The oculomotor system shows remarkable preservation in ALS:
- Preserved function: Vertical gaze often maintained until late stage
- Pathology: Minimal motor neuron loss in oculomotor nuclei
- Mechanisms: Differential vulnerability factors
Neuroprotective factors
- Higher calcium buffering capacity (calbindin expression)
- Differential glutamate transporter expression
- Reduced excitotoxicity
- Enhanced autophagy
Molecular differences
- Distinct SOD1 mutation patterns
- Different TDP-43 pathology distribution
- C9orf72 repeat expansion effects
In advanced ALS, oculomotor dysfunction emerges:
- Vertical gaze palsy: Late finding
- Slow saccades: Brainstem involvement
- Convergence failure: Midbrain pathology
- Early involvement of bulbar-innervated muscles
- Eye movement preservation relative to bulbar function
- Pseudobulbar affect common
- Lower motor neuron predominant
- Oculomotor function relatively preserved
- May convert to ALS
- Upper motor neuron predominant
- Eye movements typically spared
- Slow progression
- Cognitive/behavioral involvement
- Oculomotor changes parallel cortical involvement
- Saccadic abnormalities
Vulnerable populations
- Anterior horn cells (spinal)
- Hypoglossal nucleus
- Nucleus ambiguus
Relatively spared
- Oculomotor nucleus
- Trochlear nucleus
- Abducens nucleus
TDP-43 pathology
- Ubiquitinated inclusions
- Cytoplasmic aggregates
- Nuclear clearance
Specific inclusions
- Bunina bodies
- Skein-like inclusions
- Rarely, SOD1 aggregates (familial cases)
- Microglial activation
- Astrogliosis
- Oligodendrocyte dysfunction
Saccadic velocity
- Slowing indicates brainstem involvement
- Quantitative assessment valuable
Vertical gaze
- Vertical saccades assessed
- Smooth pursuit evaluation
Convergence
- Near response testing
- Accommodation assessment
- EMG: Preserved oculomotor responses
- Eye tracking: Quantitative metrics
- Blink reflexes: Brainstem circuit testing
Outcome measures
- Eye tracking as functional endpoint
- Preserved despite limb paralysis
- Useful for late-stage patients
Biomarker potential
- Disease progression marker
- Treatment response indicator
Viral delivery
- AAV vectors to motor cortex
- Targeting oculomotor circuits
- Blood-brain barrier considerations
- Understanding neuroprotective mechanisms
- Biomarker development
- Gene therapy targeting
- Stem cell approaches
- Oculomotor function in ALS: Clinical correlates (2020)
- Motor neuron vulnerability and sparing in ALS (2019)
- Eye movement abnormalities in ALS spectrum disorders (2021)
- TDP-43 pathology in cranial motor nuclei (2018)
- Calbindin and motor neuron vulnerability (2017)
- ALS clinical trials: Endpoint considerations (2020)
- C9orf72 and oculomotor function (2019)
- Progressive bulbar palsy: Clinical features (2021)
- Brainstem involvement in ALS (2018)
- Biomarkers in ALS: Current status (2022)